SWP
TEVA icon

Strategic Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Strategic Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-180
Closed -$3.02K – 1384
2025
Q2 		$3.02K Buy
+180
New +$2.9K ﹤0.01% 971
2019
Q4 		– Sell
-500
Closed -$3 – 462
2019
Q3 		$3 Hold
500
– – ﹤0.01% 681
2019
Q2 		$4K Hold
500
– – ﹤0.01% 665
2019
Q1 		$8K Hold
500
– – ﹤0.01% 584
2018
Q4 		$9K Hold
500
– – ﹤0.01% 514
2018
Q3 		$11K Hold
500
– – 0.01% 436
2018
Q2 		$12K Hold
500
– – 0.01% 497
2018
Q1 		$9K Sell
500
-200
-29% -$3.9K ﹤0.01% 575
2017
Q4 		$9K Buy
+700
New +$10.5K 0.01% 553

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Strategic Wealth Partners's TEVA Position: Q3 2025 in Review

Strategic Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 180 shares — an estimated $3.02K sold.

Strategic Wealth Partners first reported a position in TEVA in Q4 2017 and held it in 9 quarters. The position peaked at $12K in Q2 2018. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Strategic Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Strategic Wealth Partners sold 180 Teva Pharmaceuticals shares in Q3 2025, an estimated $3.02K.
  • Strategic Wealth Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 9 quarters.
  • Strategic Wealth Partners's Teva Pharmaceuticals position peaked at $12K in Q2 2018.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Strategic Wealth Partners's 13F filing for Q3 2025, filed 14 Nov 2025.